title: Drug susceptibility of isolates from severe postoperative intraperitoneal infections causing multiple organ failure.
abstract: OBJECTIVE
  To select the most appropriate antibiotic regimens for life-threatening postoperative infections, we obtained isolates from patients with severe postoperative infections over a 12-year-period, and examined their drug susceptibility.
  
  
  METHODS
  The subjects of this study were 55 patients with multiple organ failure (MOF) caused by postoperative infection.
  
  
  RESULTS
  All strains of Methicillin-resistant Staphylococcus aureus (MRSA) were susceptible to Vancomycin (VCM) and Teicoplanin (TEIC). Only 0.3% of all the Pseudomonas aeruginosa strains were resistant to Imipenem (IPM), but 53.6% of the strains from the severe infections were resistant to IPM. On the other hand, there were few P. aeruginosa strains resistant to Meropenem (MEPM), Ceftazidime (CAZ), Ciprofloxacin (CPFX), and Pazufloxacin (PZFX), even among strains isolated from severe infections. The resistant rate of Bacteroides fragilis to Clindamycin (CLDM) was 35.9%, but there were strains resistant to IPM and Panipenem.
  
  
  CONCLUSIONS
  These findings suggest that VCM or TEIC are most appropriate for severe abdominal abscess caused by MRSA, whereas MEPM, CAZ, CPFX, and PZFX are more effective against P. aeruginosa infections. The only antibiotic effective against B. fragilis infections in this study was IPM.
authors.affiliation: Third Department of Surgery, Toho University, School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo 153-8515, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Kusachi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Sumiyama
authors.forename: Jiro
authors.initials: J
authors.lastname: Nagao
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Arima
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Hidenori
authors.initials: H
authors.lastname: Tanaka
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Saida
authors.forename: Manabu
authors.initials: M
authors.lastname: Watanabe
authors.forename: Junko
authors.initials: J
authors.lastname: Sato
mesh_terms: D018784:Abdominal Abscess / Q000188:drug therapy / Q000382:microbiology*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001442:Bacteroides Infections / Q000188:drug therapy; D001441:Bacteroides fragilis / Q000187:drug effects; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009102:Multiple Organ Failure / Q000382:microbiology*; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology*; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents